Table 5.
Homozygote (TT vs. CC) | Heterozygote (CT vs. CC) | Dominant (TT+CT vs. CC) | Recessive (TT vs. CT+CC) | Allelic (T vs. C) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Groups | Cases/Controlsa |
ORb (95% CI) |
Pc | I2 |
ORb (95% CI) |
Pc | I2 |
ORb (95% CI) |
Pc | I2 |
ORb (95% CI) |
Pc | I2 |
ORb (95% CI) |
Pc | I2 |
All studies | 15,954/19,594 | 0.89 (0.77–1.02) | <1e−4 | 64.2 | 0.96 (0.87–1.05) | 0.008 | 37.1 | 1.00 (0.90– 1.11) | <1e−4 | 53.5 | 1.00 (0.92–1.08) | <1e−4 | 48.6 | 0.96 (0.88–1.04) | <1e−4 | 73.6 |
Controls in HWEd | 12,873/15,569 | 0.88 (0.75–1.04) | <1e−4 | 67 | 0.95 (0.89–1.02) | 0.054 | 29.7 | 0.98 (0.87–1.09) | 4e−4 | 50.8 | 0.98 (0.89–1.07) | <1e−4 | 51.3 | 095 (0.87–1.03) | <1e−4 | 70.8 |
QUALITY | ||||||||||||||||
High (>8) | 15,149/18,939 | 0.98 (0.87–1.11) | <1e−4 | 52.8 | 0.94 (0.88–1.00) | 0.060 | 27.4 | 0.97 (0.88–1.08) | 1e−4 | 51.3 | 1.04 (0.96–1.13) | 7e−4 | 47.3 | 1.02 (0.95–1.10) | <1e−4 | 66.3 |
Low (≤8) | 805/655 | 1.32 (1.83–1.34) | 0.183 | 35.7 | 1.25 (0.55–2.87) | 0.043 | 59.3 | 1.31 (0.69– 2.48) | 0.087 | 50.7 | 1.15 (0.90–1.46) | 0.84 | 0 | 1.19 (0.98–1.4) | 0.599 | 0f |
GENOTYPING | ||||||||||||||||
PCR–RFLP | 9,437/11,117 | 1.05 (0.90–1.22) | 0.003 | 46.6 | 1.01 (0.88–1.14) | 0.016 | 39.5 | 1.06 (0.92–1.22) | 3e−4 | 54.5 | 1.08 (0.98–1.19) | 0.028 | 36.3 | 1.08 (0.98–1.18) | <1e−4 | 64.5 |
Otherse | 6,517/8,477 | 0.94 (0.76–1.16) | 9e−4 | 61.6 | 0.88 (0.79–0.98) | 0.178 | 25 | 0.911 (0.77–1.06) | 0.018 | 48.3 | 1.0 (0.88–1.13) | 0.011 | 51.4 | 0.97 (0.88–1.08) | 6e−4 | 62.8 |
ETHNICITIES | ||||||||||||||||
Asian | 14,279/17,389 | 1.01 (0.89–1.15) | 0.0001 | 51.9 | 0.97 (0.88–1.08) | 0.006 | 40 | 0.97 (0.88–1.08) | 0.006 | 40 | 1.05 (0.98–1.13) | 0.005 | 40.6 | 1.05 (0.97–1.13) | <1e−4 | 65.1 |
Caucasians | 1,675/2,205 | 0.98 (0.48–1.96) | 0.022 | 64.9 | 0.93 (0.80–1.07) | 0.30 | 16.5 | 0.94 (0.82–1.08) | 0.13 | 43.5 | 1.04 (0.62–1.72) | 0.052 | 57.4 | 0.95 (0.72–1.27) | 0.049 | 57.9 |
CANCER CATEGORIES | ||||||||||||||||
GI | 6,508/8,150 | 0.96 (0.83–1.12) | 0.043 | 36.9 | 0.87 (0.79–0.97) | 0.57 | 0 | 0.92 (0.84–1.01) | 0.206 | 19.2 | 1.07 (0.99–1.15) | 0.079 | 31.5 | 1.01 (0.94–1.10) | 0.010 | 46 |
HNC | 2,885/3,769 | 1.35 (0.76–2.38) | 0.003 | 68.6 | 1.34 (0.82–2.19) | 0.001 | 72.2 | 1.45 (0.86–2.42) | <1e−4 | 80.3 | 1.10 (0.97–1.24) | 0.096 | 44.2 | 1.30 (0.87–1.94) | <1e−4 | 82.8 |
Others | 6,561/7,675 | 0.96 (0.78–1.19) | 0.001 | 59.5 | 0.97 (0.88–1.06) | 0.126 | 30.4 | 0.98 (0.83–1.15) | 0.010 | 51.9 | 0.99 (0.87–1.13) | 0.011 | 51.5 | 0.99 (0.89–1.11) | 2e−4 | 65.5 |
CANCER TYPES | ||||||||||||||||
BCe | 1,871/1,894 | 1.12 (0.53–2.36) | 0.014 | 71.6 | 1.02 (0.87–1.19) | 0.192 | 36.7 | 1.07 (0.59–1.93) | 0.031 | 65.9 | 1.10 (0.68–1.77) | 0.063 | 58.8 | 1.05 (0.69–1.60) | 0.005 | 76.4 |
HCC | 2,512/3,107 | 0.95 (0.68–1.34) | 0.008 | 61 | 0.91 (0.78–1.06) | 0.285 | 17.7 | 0.93 (0.72–1.20) | 0.039 | 50.6 | 0.97 (0.86–1.09) | 0.049 | 48.5 | 0.99 (0.83–1.17) | 0.003 | 65.6 |
GC | 2,527/3,399 | 0.95 (0.79–1.14) | 0.323 | 13.6 | 0.85 (0.72–1.00) | 0.493 | 0 | 0.92 (0.79–1.07) | 0.397 | 4.2 | 1.08 (0.96–1.22) | 0.319 | 14.2 | 1.01 (0.93–1.10) | 0.194 | 29.2 |
CRCe | 1,469/1,644 | 1.10 (0.86–1.40) | 0.671 | 0 | 0.85 (0.67–1.07) | 0.615 | 0 | 0.97 (0.78–1.20) | 0.704 | 0 | 1.21 (1.04–1.40) | 0.748 | 0 | 1.10 (0.98–1.23) | 0.801 | 0 |
LC | 1,714/1,559 | 1.04 (0.8246–1.31) | 0.116 | 53.5 | 1.03 (0.83–1.29) | 0.602 | 0 | 1.04 (0.84–1.29) | 0.351 | 4.3 | 0.98 (0.85–1.13) | 0.175 | 42.4 | 1.04 (0.70–1.52) | 0.157 | 45.8 |
Others | 5,861/7,991 | 1.02 (0.77–1.34) | 2e−4 | 65.2 | 1.071 (0.84–1.36) | 5e−4 | 63.5 | 1.10 (0.85–1.44) | <1e−4 | 73.5 | 1.00 (0.86–1.16) | 0.012 | 50.7 | 1.07 (0.89–1.29) | <1e−4 | 77.9 |
The overall, HWD-sensitivity and subgroup analyses.
n represents number of cases and controls in each group.
Pooled ORs and 95% confidence intervals.
P-value of the heterogeneity test.
Meta-analysis of all studies excluding those with the control group not in HWE.
These subgroups were found to be influenced by departure from HWE. Please refer to the Supplementary Table S4 for details on HWD sensitivity and adjustment analysis for these subgroups.
Although the point estimate of I2 was zero for the allele contrast in the low quality subgroup, the random effect model was used based on the 95%CI of I2 (0–69.8%) and small number of studies.
GI, Gastrointestinal tract cancers; HNC, Head and neck cancers; BC, Breast cancer; HCC, Hepatocellular cancers; GC, Gastric cancer; CRC, Colorectal cancer; LC, Lung cancer.
Significant associations are shown in boldface.